24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT02182830
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Registry
-
NCT02182830
-
- Other papers using this trial's data
- Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02182830. Randomized; double masking; primary purpose treatment. Start 2014-07-25 (actual); primary completion 2017-05-18 (actual). Results posted on 2018-07-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypertension
- Intervention (Drug)
- Empagliflozin low dose
- Intervention (Drug)
- placebo
- Intervention (Drug)
- Empagliflozin high dose
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02182830- Content hash
eafffc8b1fe5e8628aadc1bba995b292cebbf5d4fe47da9da3c43b08da69acf8